Skip to main content
user-generated· regulatory

FDA guidance delays increase by 20% under new commissioner

Market overview

Drug approval timelines will extend by an average of 20% in the first 12 months under the new FDA commissioner due to increased scrutiny and guideline revisions. This contradicts short-term market optimism.

regulatory prediction market

Implied probability (Yes)
55%

More regulatory markets

Browse all regulatory markets →

Loading…